MedTrace Logo

LINK: Aftercare Monitoring Project

NCT00265512 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 667

Last updated 2019-01-16

Study results available
· View outcomes & findings →

Summary

The prevalence of substance use disorders (SUD) in the VA is rising, making SUD(s) among the most commonly diagnosed disorders in the VA. A substantial body of data attests to the effectiveness of substance use disorder treatment; further the predictor most consistently associated with positive addiction treatment outcomes is duration. Despite the body of evidence supporting length of treatment as one of the stronger predictors of long-term SUD outcomes, only 36% of SUD treatment programs in the VA are meeting the continuing care performance criterion specified by the Office of Quality Performance. This randomized clinical trial investigates whether substance use disorder patients assigned to telephone case monitoring (TCM) for continuing care will do better than those attending face-to-face continuing care as usual (CCAU)(standard outpatient care).

Conditions

  • Alcohol Dependence
  • Drug Dependence

Interventions

BEHAVIORAL

Telephone Case Monitoring

Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.

BEHAVIORAL

Continuing Care as Usual

Continuing Care as Usual will include standard group outpatient SUD treatment.

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • John D. McKellar, PhD · VA Palo Alto Health Care System, Palo Alto, CA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-06-30
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00265512 on ClinicalTrials.gov